Viewing Study NCT01604850

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:03 PM
Ignite Modification Date: 2026-02-11 @ 6:01 AM
Study NCT ID: NCT01604850
Status: COMPLETED
Last Update Posted: 2014-05-28
First Post: 2012-05-21
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)
Sponsor: Gilead Sciences
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Chronic Hepatitis C View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Direct Acting Antiviral View
None HCV genotype 2 (GT-2) View
None HCV genotype 3 (GT-3) View
None HCV View
None Sustained Virologic Response View
None Combination Therapy View
None Treatment Experienced View
None GS-7977 View
None Ribavirin View